EP 3283118 A1 20180221 - SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES
Title (en)
SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES
Title (de)
STELLENSPEZIFISCHE ANTIKÖRPER-ARZNEIMITTEL-KONJUGATE
Title (fr)
CONJUGUÉS ANTICORPS-MÉDICAMENT SITE-SPÉCIFIQUES
Publication
Application
Priority
- GB 201506393 A 20150415
- EP 2016058371 W 20160415
Abstract (en)
[origin: WO2016166299A1] Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds PSMA, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, allows for improved safety and efficacy of the ADC.
IPC 8 full level
A61P 35/00 (2006.01); C07K 16/30 (2006.01)
CPC (source: CN EP KR US)
A61K 31/5517 (2013.01 - KR); A61K 39/44 (2013.01 - US); A61K 47/68035 (2023.08 - CN EP KR US); A61K 47/6851 (2017.08 - KR); A61K 47/6869 (2017.08 - EP KR US); A61P 35/00 (2018.01 - EP US); C07K 16/30 (2013.01 - US); C07K 16/3069 (2013.01 - CN EP KR US); Y02P 20/55 (2015.11 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2016166299 A1 20161020; AU 2016249877 A1 20171026; BR 112017022256 A2 20180731; CA 2981920 A1 20161020; CN 107683146 A 20180209; EP 3283118 A1 20180221; GB 201506393 D0 20150527; JP 2018511628 A 20180426; KR 20170137115 A 20171212; MX 2017013154 A 20180221; US 2018125994 A1 20180510
DOCDB simple family (application)
EP 2016058371 W 20160415; AU 2016249877 A 20160415; BR 112017022256 A 20160415; CA 2981920 A 20160415; CN 201680022066 A 20160415; EP 16716583 A 20160415; GB 201506393 A 20150415; JP 2017553879 A 20160415; KR 20177030351 A 20160415; MX 2017013154 A 20160415; US 201615566411 A 20160415